BioMarin Pharmaceutical (NASDAQ:BMRN) Stock Rating Lowered by Wall Street Zen

Key Points

• Wall Street Zen downgraded BioMarin Pharmaceutical from “Buy” to “Hold,” while broader analyst sentiment remains a “Moderate Buy” with an average price target of $88.38.
• BioMarin reported quarterly earnings of $1.20 per share, beating estimates of $0.95, while revenue rose 20% year over year to $989.71 million.
• Institutional ownership remains high at 98.71%, with several investment firms increasing their positions during the third quarter.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) was downgraded by equities researchers at Wall Street Zen from a "buy" rating to a "hold" rating in a research report issued to clients and investors on Saturday, Wall Street Zen reports.

A number of other equities analysts have also recently issued reports on BMRN. HC Wainwright reiterated a "neutral" rating and issued a $60.00 price target on shares of BioMarin Pharmaceutical in a research note on Thursday, September 10th. Raymond James Financial upgraded shares of BioMarin Pharmaceutical from an "outperform" rating to a "strong-buy" rating and set a $109.00 price objective for the company in a research note on Monday, October 12th. Jefferies Financial Group lifted their target price on shares of BioMarin Pharmaceutical from $104.00 to $105.00 and gave the stock a "buy" rating in a report on Monday, August 31st. Barclays lifted their target price on shares of BioMarin Pharmaceutical from $111.00 to $114.00 and gave the stock an "overweight" rating in a report on Wednesday, October 14th. Finally, William Blair upgraded shares of BioMarin Pharmaceutical to a "hold" rating in a research note on Wednesday, September 23rd. Three analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating, six have given a Hold rating and one has issued a Sell rating to the company's stock. According to data from MarketBeat.com, BioMarin Pharmaceutical presently has a consensus rating of "Moderate Buy" and an average price target of $88.38.

BioMarin Pharmaceutical Stock Up 1.8%

Shares of NASDAQ:BMRN opened at $58.51 on Friday. The stock has a fifty day simple moving average of $60.62 and a two-hundred day simple moving average of $58.44. The stock has a market capitalization of $11.33 billion, a price-to-earnings ratio of 158.14, a PEG ratio of 0.63 and a beta of 0.22. BioMarin Pharmaceutical has a 12-month low of $49.26 and a 12-month high of $70.98. The company has a current ratio of 2.39, a quick ratio of 1.32 and a debt-to-equity ratio of 0.56.

BioMarin Pharmaceutical (NASDAQ:BMRN - Get Free Report) last released its earnings results on Thursday, August 6th. The biotechnology company reported $1.20 EPS for the quarter, topping the consensus estimate of $0.95 by $0.25. BioMarin Pharmaceutical had a return on equity of 5.32% and a net margin of 2.14%. The business had revenue of $989.71 million for the quarter, compared to the consensus estimate of $932.03 million. During the same period in the previous year, the company posted $1.44 earnings per share. The company's revenue for the quarter was up 20.0% compared to the same quarter last year. BioMarin Pharmaceutical has set its FY 2026 guidance at 4.900-5.100 EPS. On average, research analysts anticipate that BioMarin Pharmaceutical will post 2.59 earnings per share for the current fiscal year.

Institutional Investors Weigh In On BioMarin Pharmaceutical

Institutional investors have recently modified their holdings of the business. Oregon Public Employees Retirement Fund boosted its holdings in shares of BioMarin Pharmaceutical by 0.5% in the third quarter. Oregon Public Employees Retirement Fund now owns 40,117 shares of the biotechnology company's stock worth $2,407,000 after buying an additional 200 shares during the last quarter. Bank Julius Baer & Co. Ltd Zurich bought a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $186,000. Mirae Asset Global Investments Co. Ltd. bought a new stake in BioMarin Pharmaceutical during the third quarter valued at approximately $705,000. Profund Advisors LLC increased its holdings in BioMarin Pharmaceutical by 34.3% during the third quarter. Profund Advisors LLC now owns 37,548 shares of the biotechnology company's stock valued at $2,253,000 after buying an additional 9,582 shares during the last quarter. Finally, Vise Technologies Inc. increased its holdings in BioMarin Pharmaceutical by 125.1% during the third quarter. Vise Technologies Inc. now owns 12,096 shares of the biotechnology company's stock valued at $726,000 after buying an additional 6,722 shares during the last quarter. 98.71% of the stock is owned by hedge funds and other institutional investors.

About BioMarin Pharmaceutical

BioMarin Pharmaceutical Inc is a biotechnology company focused on developing and commercializing therapies for serious and life-threatening rare diseases. The company's research and development efforts center on genetic and metabolic disorders, where patient populations are often small and treatment options are limited.

BioMarin's marketed products include Voxzogo (vosoritide) for children with achondroplasia and open growth plates, Palynziq (pegvaliase) and Kuvan (sapropterin dihydrochloride) for phenylketonuria, Brineura (cerliponase alfa) for late-infantile neuronal ceroid lipofuscinosis type 2, Vimizim (elosulfase alfa) for Morquio A syndrome, and Naglazyme (galsulfase) for mucopolysaccharidosis VI.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.